AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of ...
The final 2025 KDIGO Guideline suggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function CHELMSFORD, Mass. & TOKYO, November 04, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results